Caseware UK (AP4) 2025.0.111 2025.0.111 2025-08-312025-08-318true2024-09-01falseDispensing chemist9trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 06973505 2024-09-01 2025-08-31 06973505 2023-09-01 2024-08-31 06973505 2025-08-31 06973505 2024-08-31 06973505 c:Director1 2024-09-01 2025-08-31 06973505 d:MotorVehicles 2024-09-01 2025-08-31 06973505 d:MotorVehicles 2025-08-31 06973505 d:MotorVehicles 2024-08-31 06973505 d:MotorVehicles d:OwnedOrFreeholdAssets 2024-09-01 2025-08-31 06973505 d:FurnitureFittings 2024-09-01 2025-08-31 06973505 d:FurnitureFittings 2025-08-31 06973505 d:FurnitureFittings 2024-08-31 06973505 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-09-01 2025-08-31 06973505 d:OfficeEquipment 2024-09-01 2025-08-31 06973505 d:OfficeEquipment 2025-08-31 06973505 d:OfficeEquipment 2024-08-31 06973505 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-09-01 2025-08-31 06973505 d:ComputerEquipment 2024-09-01 2025-08-31 06973505 d:ComputerEquipment 2025-08-31 06973505 d:ComputerEquipment 2024-08-31 06973505 d:ComputerEquipment d:OwnedOrFreeholdAssets 2024-09-01 2025-08-31 06973505 d:OwnedOrFreeholdAssets 2024-09-01 2025-08-31 06973505 d:Goodwill 2025-08-31 06973505 d:Goodwill 2024-08-31 06973505 d:CurrentFinancialInstruments 2025-08-31 06973505 d:CurrentFinancialInstruments 2024-08-31 06973505 d:Non-currentFinancialInstruments 2025-08-31 06973505 d:Non-currentFinancialInstruments 2024-08-31 06973505 d:CurrentFinancialInstruments d:WithinOneYear 2025-08-31 06973505 d:CurrentFinancialInstruments d:WithinOneYear 2024-08-31 06973505 d:Non-currentFinancialInstruments d:AfterOneYear 2025-08-31 06973505 d:Non-currentFinancialInstruments d:AfterOneYear 2024-08-31 06973505 d:Non-currentFinancialInstruments d:MoreThanFiveYears 2025-08-31 06973505 d:Non-currentFinancialInstruments d:MoreThanFiveYears 2024-08-31 06973505 d:ShareCapital 2025-08-31 06973505 d:ShareCapital 2024-08-31 06973505 d:CapitalRedemptionReserve 2024-09-01 2025-08-31 06973505 d:CapitalRedemptionReserve 2025-08-31 06973505 d:CapitalRedemptionReserve 2024-08-31 06973505 d:RetainedEarningsAccumulatedLosses 2024-09-01 2025-08-31 06973505 d:RetainedEarningsAccumulatedLosses 2025-08-31 06973505 d:RetainedEarningsAccumulatedLosses 2024-08-31 06973505 c:FRS102 2024-09-01 2025-08-31 06973505 c:AuditExemptWithAccountantsReport 2024-09-01 2025-08-31 06973505 c:FullAccounts 2024-09-01 2025-08-31 06973505 c:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 06973505 2 2024-09-01 2025-08-31 06973505 6 2024-09-01 2025-08-31 06973505 e:PoundSterling 2024-09-01 2025-08-31 iso4217:GBP xbrli:pure

Registered number: 06973505










CALDERDALE HEALTH FOCUS LTD








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 AUGUST 2025

 
CALDERDALE HEALTH FOCUS LTD
 
  
CHARTERED ACCOUNTANTS' REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OFCALDERDALE HEALTH FOCUS LTD
FOR THE YEAR ENDED 31 AUGUST 2025

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Calderdale Health Focus Ltd for the year ended 31 August 2025 which comprise the Balance sheet and the related notes from the Company's accounting records and from information and explanations you have given to us.
 

This report is made solely to the director of Calderdale Health Focus Ltd in accordance with the terms of our agreement. Our work has been undertaken solely to prepare for your approval the financial statements of Calderdale Health Focus Ltd and state those matters that we have agreed to state to him in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Calderdale Health Focus Ltd and its  director for our work or for this report.
 
 
It is your duty to ensure that Calderdale Health Focus Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the Company's assets, liabilities, financial position and profit. You consider that Calderdale Health Focus Ltd is exempt from the statutory audit requirement for the .
 
 
We have not been instructed to carry out an audit or review of the financial statements of Calderdale Health Focus Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.





Shipleys Tax & Accounts

27 August 2026
Page 1

 
CALDERDALE HEALTH FOCUS LTD
REGISTERED NUMBER: 06973505

BALANCE SHEET
AS AT 31 AUGUST 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 6 
17,258
30,612

Investments
 7 
587,925
587,925

  
605,183
618,537

Current assets
  

Stocks
  
194,250
12,270

Debtors: amounts falling due within one year
 8 
387,341
1,851,273

Cash at bank and in hand
 9 
51,947
19,318

  
633,538
1,882,861

Creditors: amounts falling due within one year
 10 
(213,527)
(290,108)

Net current assets
  
 
 
420,011
 
 
1,592,754

Total assets less current liabilities
  
1,025,194
2,211,291

Creditors: amounts falling due after more than one year
 11 
-
(3,979)

  

Net assets
  
1,025,194
2,207,312


Capital and reserves
  

Called up share capital 
  
100
200

Capital redemption reserve
 13 
100
-

Profit and loss account
 13 
1,024,994
2,207,112

  
1,025,194
2,207,312


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 27 August 2026.
Page 2

 
CALDERDALE HEALTH FOCUS LTD
REGISTERED NUMBER: 06973505

BALANCE SHEET (CONTINUED)
AS AT 31 AUGUST 2025





Qamar Ayub
Director

The notes on pages 4 to 10 form part of these financial statements.

Page 3

 
CALDERDALE HEALTH FOCUS LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025

1.


General information

Calderdale Health Focus Ltd is a company domiciled in England & Wales, registration number 06973505. The registered office is 210-212 Kings Cross Road, Halifax, West Yorkshire, HX1 3JP.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 4

 
CALDERDALE HEALTH FOCUS LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025

2.Accounting policies (continued)

 
2.3

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

 
2.4

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.5

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.6

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.7

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


 
2.8

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 
2.9

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 5

 
CALDERDALE HEALTH FOCUS LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025

2.Accounting policies (continued)


2.9
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Motor vehicles
-
25% straight line
Fixtures & fittings
-
20% straight line
Office equipment
-
20% straight line
Computer equipment
-
33% straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.10

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of comprehensive income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.

 
2.11

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a weighted average basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.12

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.13

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Page 6

 
CALDERDALE HEALTH FOCUS LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025

2.Accounting policies (continued)

 
2.14

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.15

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 8 (2024 - 9).


4.


Dividends

2025
2024
£
£


Dividends paid on equity capital
106,000
120,000

106,000
120,000


5.


Intangible assets




Goodwill

£





At 1 September 2024
947,996



At 31 August 2025

947,996





At 1 September 2024
947,996



At 31 August 2025

947,996



Net book value



At 31 August 2025
-



At 31 August 2024
-


Page 7

 
CALDERDALE HEALTH FOCUS LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025

6.


Tangible fixed assets


Motor vehicles
Fixtures & fittings
Office equipment
Computer equipment
Total

£
£
£
£
£



Cost or valuation


At 1 September 2024
53,804
31,144
5,231
25,254
115,433


Additions
-
-
-
1,166
1,166



At 31 August 2025

53,804
31,144
5,231
26,420
116,599



Depreciation


At 1 September 2024
32,920
24,380
4,448
23,073
84,821


Charge for the year on owned assets
6,961
5,050
274
2,235
14,520



At 31 August 2025

39,881
29,430
4,722
25,308
99,341



Net book value



At 31 August 2025
13,923
1,714
509
1,112
17,258



At 31 August 2024
20,884
6,764
783
2,181
30,612


7.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


At 1 September 2024
587,925



At 31 August 2025
587,925





8.


Debtors

2025
2024
£
£


Trade debtors
109,976
92,357

Amounts owed by group undertakings
93,873
1,172,001

Other debtors
150,159
533,582

Prepayments and accrued income
33,333
53,333
Page 8

 
CALDERDALE HEALTH FOCUS LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025

8.Debtors (continued)


387,341
1,851,273



9.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
51,947
19,318

51,947
19,318



10.


Creditors: Amounts falling due within one year

2025
2024
£
£

Trade creditors
26,460
23,630

Corporation tax
18,379
170,347

Other taxation and social security
-
5,740

Other creditors
115,740
35,435

Accruals and deferred income
52,948
54,956

213,527
290,108



11.


Creditors: Amounts falling due after more than one year

2025
2024
£
£

Bank loans
-
3,979

-
3,979


Page 9

 
CALDERDALE HEALTH FOCUS LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025

12.


Loans


Analysis of the maturity of loans is given below:


2025
2024
£
£




Amounts falling due after more than 5 years

Bank loans
-
3,979

-
3,979

-
3,979



13.


Reserves

Capital redemption reserve

This reserve consists of shares redeemed by the company.

Profit & loss account

This reserve includes all current and prior period retained profits and losses.


14.


Related party transactions

During the year the director repaid the company £134,238 (2024: £18,891) and loaned a further £71,426. At the balance sheet date other creditors included £71,426 (2024: £134,238 - other debtors) as amounts owed to the director.

During the year Aarmco Ltd (a company owned by one of the shareholders) repaid the company £105,000. At the balance sheet date other debtors included £104,500 
(2024: £209,500) as amounts owed by Aarmco Ltd.

During the year the company's subsidiary J. Swire & Son Ltd repaid the company £1,078,128. At the balance sheet date other debtors included £93,873 
(2024: £1,172,001) as amounts owed by J. Swire & Son Ltd.


15.


Controlling party

There is no controlling party.


Page 10